CCM
PDSB icon

Chiron Capital Management’s PDS Biotechnology PDSB Stock Holding History

Chiron Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-500
Closed -$1K – 341
2020
Q3 		$1K Buy
+500
New +$1.4K ﹤0.01% 477

Other funds holding PDSB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Chiron Capital Management's PDSB Position: Q4 2020 in Review

Chiron Capital Management sold out of PDS Biotechnology (PDSB) in Q4 2020, closing a stake of 500 shares — an estimated $1K sold.

Chiron Capital Management first reported a position in PDSB in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 30 funds tracked by Wall St. Rank hold PDSB as of Q4 2020.

  • Chiron Capital Management reported no remaining PDS Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 500 PDS Biotechnology shares in Q4 2020, an estimated $1K.
  • Chiron Capital Management first reported a position in PDS Biotechnology in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's PDS Biotechnology position peaked at $1K in Q3 2020.
  • 30 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.